Featured Perrigo

Private Brand Baby Formula Receives An “A” Rating From Doctors

\"perrogo-formula\"Perrigo Nutritionals announced today that private brand Advantage infant formula, sold as a private brand product, received high marks from pediatricians in a new infant formula survey by Clinician Reports. The July 2016 Pediatrics Issue reports that store brand Advantage infant formula compares favorably to the nutrition of the nationally advertised brand, Similac Advance Infant Formula.

Clinician Reports asked 20 independent pediatricians to test store brand Advantage infant formula with their newborn patients for eight weeks. Overall, store brand Advantage received an \”A\” rating with high marks in all categories. Pediatricians found the store brand nutritionally comparable to the nationally advertised brand, well tolerated by infants, easy to prepare, and a great value for the money.

Perrigo\’s Executive Vice President & President, Consumer Healthcare – Americas, Jeff Needham stated, \”It comes as no surprise that store brand Advantage infant formula received high marks from healthcare professionals in this survey. All infant formulas sold in the United States must meet the same FDA standards. More and more pediatricians and consumers realize high quality store brands are nutritionally comparable to nationally advertised brands and offer more value with up t0 50% savings versus national brands.\”

Clinician Reports is the home of peer-approved medical tools and therapies. The resource is designed to help the clinician instantly find FDA-approved cleared products with peer reviews, clinical results, FDA approval/clearance letters, and testimonials. Read the report in the Pediatrics July issue at  Interactive results can also be viewed online at

Featured Perrigo

Perrigo Issues Recall For Private Brand Children’s Cold Medicine

\"CoughPrivate Brand manufacturer Perrigo announced today that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail level of 2 batches of its children\’s guaifenesin grape liquid (100mg/5 mL) and 3 batches of its children\’s guaifenesin DM cherry liquid (100mg guaifenesin and 5mg dextromethorphan HBr/ 5 ml) sold in 4 oz. bottles with dosage cup in a box under the store brand products listed below. This recall is being initiated because some packages contain an oral dosing cup with incorrect dose markings.

Use of these products according to labeled instructions with an affected dosing cup is unlikely to result in serious side effects, and no reports related to overdose have been received to date. Consumers should be aware that an overdose of Guaifenesin DM may cause hyper excitability, rapid eye movements, changes in muscle reflexes, ataxia, dystonia, hallucinations, stupor, and coma. Other effects have included nausea, vomiting, tachycardia, irregular heartbeat, seizures, respiratory depression, and death. Gastric decontamination is recommended after acute ingestion of greater than 10 mg/kg, if administered soon after ingestion. At risk populations such as those who are poor metabolizers of dextromethorphan may experience an overdose by a factor of 3, if incorrect measuring levels are used. Additionally, small children who are poor metabolizers of dextromethorphan and use the product regularly over a period of several days at the mistaken dose, may develop cumulative toxicity. Moreover, adverse reactions to guaifenesin when given in high or excessive dosage may include nausea/vomiting, diarrhea, and/or abdominal pain. Therefore, an extreme overdose in an at risk population may need medical intervention, but in most cases adverse health consequences are temporary and reversible.

Commenting on this market action, Perrigo\’s Chairman and CEO Joseph C. Papa stated, “There have been no reports of adverse events to Perrigo as a result of the incorrect dosage markings. Perrigo is taking this action to maintain the highest possible product quality standards for our retail customers and consumers. We are taking this action because it is the right thing to do.”

These OTC products are indicated for helping loosen phlegm (mucus) and thin bronchial secretions and making coughs more productive, as well as in the case of the DM product to temporarily relieve: coughs due to minor throat irritations, the intensity of coughing, and the impulse to cough.  These recalled products are sold by distributors nationwide and distributed through retail stores.

Perrigo is notifying its distributors and customers by verbal and e-mail communication, followed by formal FedEx-delivered communication. It also is arranging for return of all recalled products. Distributors/retailers that have the affected batches of children\’s guaifenesin grape liquid and/or children\’s guaifenesin DM cherry that is being recalled should stop distribution and return product.

Consumers that have product with the corresponding labels and batch numbers listed below should discard the dosing device and product and may call Perrigo, toll free, Monday through Friday from 8:00 AM to 10:00 PM EST, at 1-888-345-0479, or visit Consumers should contact their physician or healthcare provider if they have any questions, or if they or their children experience any problem that could possibly be related to this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA\’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Recalled lots, along with their corresponding branded labels, are listed below:


Label Lot number Expiry
H.E.B 5LK0592 08/2017
CVS 5MK0340 08/2017



Label Lot number Expiry
Sunmark 5LK0528, 5LK0630 03/2017
Rite-Aid 5LK0528, 5LK0630 03/2017
Topcare 5LK0528, 5LK0630, 5LK0779 03/2017
Kroger 5LK0528, 5LK0630 03/2017
GoodSense 5LK0528 03/2017
Dollar General 5LK0630 03/2017
Care One 5LK0630 03/2017
CVS 5LK0630 03/2017


2014 Perrigo

PB CAREERS: Perrigo – Store Brand Marketing Manager

\"PERRIBOX_TU_C_^_TUESDAY\"Perrigo – Store Brand Marketing Manager

Tracking Code: 2011852
Job Description
Position Overview:
Be a marketer in one of the world’s most innovative companies (according to Forbes magazine).

Primary marketing responsibilities for OTC healthcare categories that compete in a $5-7Billion retail market place.

Major Responsibilities:

  • Provides organizational thought and strategic leadership for assigned base business categories
  • Monitor and manage trends in related market segments
  • Managing the product lifecycle for products in assigned categories
  • Commercial team subject matter expert for products in assigned categories
  • Develop strategies to achieve the sales plan/forecast and profitability targets for assigned categories
  • Development of category reviews and attends customer sales calls for category reviews
  • Assists in the development of OTC promotional materials

Required Skills

  • Bachelor degree in Business, Marketing or a related field is required, with a Master in Business Administration preferred
  • 7 plus years’ experience of relevant marketing experience
  • Thorough knowledge of OTC pharmaceuticals and the Store Brand Industry as a plus
  • Experience in being responsible for over $300 million in sales volume
  • Demonstrated ability to develop and execute a business plan
  • Excellent project and time management skills
  • Excellent verbal and written communication skills
  • Highly experienced with working with retail headquarter buyers for major retailers (mass, drug, grocery, etc.)
  • Presentation experience before internal senior leadership
  • Ability to drive internal teams and develop a sense of urgency
  • Works largely autonomously
  • Experienced with syndicated data
  • Advanced skills in Microsoft Excel, Word, Outlook, and Power Point
  • Advanced skills working with syndicated data
  • Ability to travel up to 30% of the time

An Equal Opportunity Employer – M/F/D/V

Job Location: Allegan, Michigan, United States
Position Type: Full-Time/Regular
Position Physical Requirements: N/A


Manufacturers Perrigo

Perrigo Buys Irish Biotech Firm Elan Corporation For $8.6 billion

\"elan\"Allegan, Michigan based Private Brand drug manufacturer Perrigo will buy Irish biotech company Elan Corporation for $8.6 billion, in a cash and stock deal, the companies announced on Monday, in a joint statement.

\"PerrigoLogo\"Perrigo will pay $6.25 a share in cash and 0.07636 shares of Perrigo — the proposed new company combining Perrigo and Elan — valued at $10, for each Elan share. The offer price is at a premium of about 10.5% over Elan’s closing price on Friday.

The deal is expected to help Perrigo save $150 million in taxes and operating expenses, as it will allow the company to move its headquarters to Ireland – where Elan is based — which has a low corporate tax rate of 10.5%, compared to the 30% tax rate in the U.S.

“Certain of these synergies result from the elimination of redundant public company costs while optimizing back-office support and the global R&D functions. Additionally, tax savings are expected to arise from the combined company being incorporated in Ireland with organizational, operations and capitalization structures that will enable the combined company to more efficiently manage its global cash and treasury operations,” Joseph C. Papa, Perrigo Chairman and CEO, said in a news release.



Perrigo Launches First-Ever Marketing Campaign For Private Brand OTC Medications

\"StorePerrigo Company announced yesterday that it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter (OTC) medications sold at leading retailers – also known as \”store brand\” OTCs.

Referencing other successful industry branding campaigns like \”Got Milk?\” or \”Pork: The Other White Meat,\” Perrigo\’s primary objective for the \”Store Brand Meds\” campaign is to better educate consumers on the quality, value and effectiveness of store brand medications. All store brand medications sold in the U.S. must adhere to the same high-quality FDA regulations and guidelines as the national brands. The FDA generally mandates store brands contain the same active ingredients in the same strength, and offer the same symptom relief as their national brand counterparts. Store brand medications are available at most retailers in their own labels or as private brands.

Store brand sales account for 35% of the dollar share of all OTCs sold at retail today, but misperceptions about their quality and effectiveness still exist among some consumers. The Store Brand Meds campaign is intended to address such misperceptions. The campaign relies heavily on social media, leveraging the campaign\’s recently launched Facebook page, YouTube channel and Website to spread the word.

Since the campaign\’s “soft launch” in January 2013, consumers have a new opportunity to learn about and engage with Store Brand Meds via its Facebook page in a fun, but informative way. The campaign\’s videos on YouTube now have more than 3.2 million views. The company is also making significant investments in digital advertising, public relations and electronic couponing to drive more awareness about the campaign.

Although it varies by category, Perrigo estimates that a customer will save an average of 36% by purchasing the store brand instead of the name brand. According to Perrigo, the company\’s store brand OTCs save consumers around $5 billion annually.

“Although we continue to see growing acceptance among consumers for store brand medications, questions and misinformation are still out there,” said Jeff Needham, Perrigo\’s executive vice president and general manager for U.S. consumer healthcare. “We know there is a real benefit to helping educate consumers on how store brands are regulated, made and sold. It helps us, it helps the industry, it helps our retailers, and, most important, it empowers consumers by giving them the facts and information they need to make purchase decisions.”